34 % moderate disease. CSS was associated with a significantly higher risk of poorly controlled hyperthyroidism at 6 months. Conclusions In Italy, a relevant proportion of Graves' patients at diagnosis have mild to moderate GD; about half of them have no goiter, slightly less than one-fifth have subclinical hyperthyroidism, and only 20 % have GO. Thus, the clinical phenotype of GD is milder than in the past, possibly due to both earlier diagnosis and treatment, and improved iodine nutrition.
Introduction
Graves' disease is an autoimmune disease and the most frequent cause of hyperthyroidism in iodine-replete areas [1] , where it accounts for 50-80 % of cases of hyperthyroidism [2] . While both genetic and non-genetic factors contribute to its pathogenesis [3] , the ultimate cause of hyperthyroidism is represented by antibodies binding to the TSH receptor on thyroid follicular cells, thereby causing uncontrolled stimulation of thyroid function and growth (TSH receptor antibody, TRAb) [4] . In 1840, Carl Adolph von Basedow [5] provided a description of four patients (three women and one man) affected with this disease and characterized by the so-called Merseburg triad (exophthalmos, goiter, and palpitations). Indeed, in addition to palpitations, other classical symptoms and signs of hyperthyroidism were described, including tremors, sweating, restlessness, diarrhea [5] . Nowadays, exophthalmos (Graves' orbitopathy, GO), even though the most frequent extrathyroidal 1 3 manifestation of Graves' disease [6] , seems to be less frequent than in the past; it affects about 25 % of newly diagnosed Graves' patients [7] , is usually mild, and rarely progresses to more severe forms [8] . This different phenotype of GO might be related to early diagnosis and prompt correction of hyperthyroidism, which may produce a beneficial effect on GO [9] .
As far as thyroid size is concerned, a Danish study published 30 years ago reported that goiter, assessed by palpation, was present in 80 of 99 newly diagnosed Graves' patients (81 %), being small in 58 % and moderate to large in 23 % [10] . Twenty years ago, a large observational, longitudinal study from Italy reported that moderate to large goiters, assessed by ultrasonography, were found in 52 % of Graves' patients, whereas 48 % have smaller goiters [11] . In recent years, we had the impression that, in addition to the decreased prevalence of GO, the prevalence of goiter and the severity of hyperthyroidism also decreased in patients with Graves' disease being diagnosed in the same geographical area (Central/Northern Italy).
Aim of this observational, longitudinal study was to investigate in recent years the components of the Merseburg triad in a large population of newly diagnosed Graves' patients.
Materials and methods

Study group
The study group included 283 patients with newly diagnosed Graves' disease (200 from Varese, 83 from Pavia), who were enrolled during the years 2010-2014. The diagnosis of Graves' disease was based on standard criteria, including positive tests for TSH receptor autoantibody (TRAb), suppressed serum TSH levels with increased/ normal serum-free thyroxine (FT4) and triiodothyronine (FT3) levels, diffuse uptake at thyroid scan, hypoechoic ultrasonographic features, and the presence of GO. The demographic, clinical, and laboratory features of enrolled patients are presented in Table 1 . Patients previously treated for hyperthyroidism or aged <18 years were excluded, as well as patients who were submitted to radioiodine treatment, thyroidectomy or were lost to follow-up. There were no significant differences in the baseline characteristics of patients from Varese and Pavia. After diagnosis, antithyroid drug (ATD) treatment, using methimazole with the titration method, was initiated and maintained for 18-24 months. The starting daily dose ranged 15-30 mg, and the maintenance dose ranged 2.5-10 mg in most cases. Patients were reevaluated at 6 and 12 months. In addition to the evaluation of the baseline phenotype of Graves' disease, aim of the study was to assess whether baseline characteristics could be related to the control at 6 and 12 months. Full data on relapses after the end of ATD treatment are not available for the time being.
Thyroid volume
Thyroid volume was assessed by ultrasonography, using the ellipsoid formula: width (mm) × length (mm) × thickness (mm) × 0.52 × each lobe = volume (ml). [11] . The upper limit of the normal range in our areas is ≤18 ml in men and ≤14 ml in women [11] .
Assessment of Graves' orbitopathy
GO severity and activity were assessed as proposed by the European Group on Graves' Orbitopathy (EUGOGO) [12] . GO severity was classified as absent, mild, moderate to severe, and sight-threatening and considered active when the Clinical Activity Score (CAS) was ≥3/7 [12] .
Assays
Serum TSH and FT 4 were measured by specific RIAs (Liason ® Dia Sorin). Reference ranges are: TSH 0.31-5 mU/l and FT 4 7.8-18 pg/ml, respectively. TRAb levels were measured by second-generation radioreceptor assay (Thermofisher, Germany); thyroid peroxidase antibody (TPOAb) was assayed by solid-phase RIA (Thermofisher, Germany). Normal values for TRAb and TPOAb are <1 U/l and <60 mU/ml, respectively.
Clinical Severity Score of Graves' disease
To classify the severity of Graves' disease at presentation, we designed a clinical severity score (CSS, Table 2 ) considering the three components of the Merseburg triad (goiter, hyperthyroidism, and GO). For each component, we defined 4 categories: category 1 (serum FT4 within the normal limits; normal thyroid volume; absent GO), category 2 (serum FT4 or thyroid volume ≤1.5-fold above the upper normal limit; mild GO), category 3 (serum FT4 or thyroid volume >1.5-fold but ≤2.5-fold above the upper normal limit; moderate to severe GO), and category 4 (serum FT4 and thyroid volume >2.5-fold above the upper normal limit; sight-threatening GO). One point was given to category 1, two points to category 2, four points to category 3, and eight points to category 4. The severity score was the sum of the points given to the three components and could range from 3 to 24. Graves' disease was defined as mild if CSS was between 3 and 5, moderate for scores between 6 and 8, and severe for scores ≥9 (Table 2) .
Statistical analysis
We summarized the main demographic and clinical features at the study inclusion visit of the n = 283 patients using means and standard deviations, or prevalence, for continuous and categorical variables, respectively. Variables presenting a skewed distribution were summarized using the median and the interquartile range. Descriptive statistics were estimated in the overall patient population, as well as by categories of thyroid volume defined as no goiter, small goiter, moderate goiter, and large goiter. To test the statistical significance of the association between demographic and clinical features with thyroid volume, we used F-test and Chi-square test for continuous and categorical We analyzed the association between goiter, hyperthyroidism, and the CSS at the initial visit with the lack of control of hyperthyroidism at months 6 and 12, defined as TSH ≤0.1 mU/l. Thirty-two patients did not have TSH determination at month 6. With respect to patients with complete data, these patients had slightly lower FT4 values at baseline (median 24.9 vs. 28.8 pg/ml; p = 0.03); they were included in the 12-month analysis only. We estimated the relative risks and their 95 % confidence intervals of hyperthyroidism at months 6 and 12 for categories of thyroid volume (reference: no goiter), serum FT4 values (4 categories based on sample quartiles), and severity of Graves' disease (reference: mild disease) from univariate Poisson regression models, adjusting for age, sex, current smoking, family history of thyroid disease, and the presence of thyroid nodules. The significance level was set at α = 0.05. All the analyses were conducted using the SAS statistical software, 9.4 release (Copyright (c) 2002-2012 by SAS Institute Inc., Cary, NC, USA). Table 1 shows the baseline characteristics of the patients enrolled in this study of newly diagnosed Graves' disease. There was a large preponderance of women, with a female/male ratio of 3:1. The mean age at diagnosis was 47.4 years, and the prevalence peak was in the 5th decade of life. The increase in thyroid volume was associated with an increase in the prevalence of GO, severity of hyperthyroidism, and serum TRAb levels (Table 1) . T3-toxicosis (normal FT4 and increased FT3) was found in only 10 patients. Although differences in the duration of disease were not significant, there was a trend toward a longer duration of disease among patients with goiters of moderate and large size ( Table 1) . The prevalence of current smokers was around 30 %, and no significant association was found between smoking habits and goiter size. GO was present in only 20 % of patients at diagnosis and was mild and inactive in the large majority of them. A CAS ≥3, indicating active GO, was observed in only 2.5 % of patients. Thyroid nodules were detected in about 30 % of the patients, but no information is available as to whether they preexisted to the onset of Graves' hyperthyroidism. A family history for thyroid diseases, which was positive in about half of the patients, was significantly related to the size of goiter. TPOAb tests were positive in two-thirds of the patients. Figure 1 shows that, at diagnosis, 45 % of patients had a normal thyroid volume (no goiter, i.e., ≤18 ml in men, ≤14 ml in women), 30 % had a small goiter (less than 1.5-fold above upper limit of normal), 18 % a goiter of moderate size (between 1.5 and 2.5-fold above upper limit of normal), and only 7 % had a large goiter (>2.5-fold above upper limit of normal). When thyroid volumes were stratified according to the criteria used by Vitti et al. [11] , i.e., ≤40, 41-70, >70 ml, 269 of 283 patients (95 %) had a thyroid volume ≤40 ml, and 14 patients (5 %) between 41 and 70 ml. No patient had a goiter larger than 70 ml.
Results
According to previously defined criteria, 16 % of patients had subclinical hyperthyroidism (suppressed serum TSH and normal serum FT4 levels) (Fig. 2) ; hyperthyroidism was mild (serum FT4 between 18.1 and 27 pg/ml) in 29 % of patients, moderate (serum FT4 between 27.1 and 45 pg/ml) in 41 %, and severe (serum FT4 >45 pg/ml) in only 14 % of them (Fig. 2) .
To define the overall severity of Graves' disease, we assigned a score to each component of the Merseburg triad, based on the degree of goiter, hyperthyroidism, and GO. Accordingly, a severity score was developed, as reported under Materials and Methods. At diagnosis, less than half (44 %) of the patients had severe Graves' disease, while 22 % of them had mild disease and 34 % moderate disease (Fig. 3) . We then evaluated whether baseline characteristics were associated with a poor control of hyperthyroidism after 6 and 12 months of ATD treatment. As illustrated in Table 3 , neither baseline thyroid volume nor serum FT4 levels were per se associated with an increased risk of poor control of hyperthyroidism, although there was a trend for an association with serum FT4 concentration. However, the overall severity of Graves' disease, as assessed by the CSS, was associated with a significantly higher relative risk of poorly controlled hyperthyroidism at 6 months, and with a trend at 12 months (Table 3) .
Discussion
Graves' disease is classically described as characterized by the Merseburg triad, i.e., goiter, palpitations (hyperthyroidism), and exophthalmos (GO) [13] . However, clinical features of patients at diagnosis are heterogeneous and may have been changing recently. Aim of our study was to evaluate the characteristics of a large cohort of Graves' patients of recent onset and to compare them with previous studies from the same geographical area. A few years ago, in a large cohort of patients enrolled between 2002 and 2009, we reported that GO at diagnosis was present in only about 25 % of patients, was usually mild, and was rarely progressive [7, 8] . This low prevalence of GO is confirmed by the present study, in which at disease onset only 20 % patients had GO, and this was generally mild and inactive. A possible explanation for these findings might be a better interaction between ophthalmologists and endocrinologists, leading to early referral and to a better and prompter control of environmental, modifiable risk factors for GO, including smoking habit [14] and, most importantly, thyroid dysfunction [15] [16] [17] .
Goiter is another mainstay of Graves' disease phenotype. The disease may develop on a preexisting nodular goiter, but in most cases, goiter results from the uncontrolled action of TRAb, which, besides causing excess thyroid hormone synthesis, can stimulate thyroid growth. This concept Table 3 Relative risk (with 95 % confidence intervals) of persistent hyperthyroidism at months 6 a and 12 according to baseline thyroid volume, serum FT4 levels, and severity score RR relative risk and 95 % CI estimated from Poisson regression models, adjusted for age, sex, smoking status at baseline, family history of thyroid disease, and the presence of thyroid nodules a N = 251 patients had TSH determination at month 6 b Categories based on sample quartiles, with cut points: 18, 27 and 44 pg/ml is supported by the clinical association of high TRAb levels and goiter [11] and by in vitro data showing that TRAb, beside cAMP production, stimulate thymidine uptake and cell replication in continuously cultured thyroid cell lines [18, 19] . Data on the prevalence of goiter in Graves' disease are conflicting and difficult to interpret because in many studies, definition and assessment of thyroid size were based on palpation, which is far less precise than the ultrasonographic assessment. In addition, differences in iodine intake among geographical areas where patients of different series were recruited might contribute to observed variations. In this regard, it is worth recalling that iodine deficiency in Italy was more severe 20-30 years ago. In our study, thyroid volume, as assessed by ultrasonography, was normal in 45 % of cases and goiter was small in 30 % of cases. This means that 75 % of Graves' patients at diagnosis had a thyroid of normal or only slightly enlarged volume. Large goiters (more than 2.5-fold above the upper limit of normal) represented only 7 % of cases. Higher serum TRAb levels were associated with a larger thyroid size, and patients with largest goiters had more severe hyperthyroidism (Table 1 ). In a study of 208 Danish patients with newly diagnosed Graves' disease, Laurberg et al. [20] reported that goiter was present in 46.9 % of men and 53.4 % of women. In older studies from Belgium [21] and Germany [22] , goiter, assessed by ultrasonography, was in present in 61-80 % of newly diagnosed Graves' patients. In Italy, iodine intake is improved after the introduction of a law in 2005 that implements iodized salt availability. Two large Italian studies from Central/Northern part of the country assessed thyroid volume by ultrasonography in newly diagnosed Graves' patients in years of more severe iodine deficiency than nowadays. Vitti et al. [11] Fig. 4 , data from the present series (patients enrolled between 2010 and 2014, i.e., 20-30 years after the above Italian studies) are quite different, because 95 % of them had a thyroid volume <40 ml, and no patient had a goiter >70 ml. The third pillar of the Merseburg triad is hyperthyroidism. In the present study, hyperthyroidism was subclinical in 16 % and mild in 29 % of patients, whereas only 14 % of patients had severe hyperthyroidism. In a large representative study of outpatients in France, subclinical hyperthyroidism was found in 4.1 % of those being diagnosed with Graves' disease [24] . This might be related to early referral and diagnosis. In our patients, we promptly initiated ATD treatment. It should, however, be noted that the natural course of subclinical hyperthyroidism due to Graves' disease is not completely understood. Interestingly enough, a recent study of 44 patients from UK diagnosed with subclinical hyperthyroidism showed that, after a median follow-up of 32 months, approximately 34 % of them progressed to overt hyperthyroidism, 34 % normalized their thyroid function, 30 % remained in a subclinical hyperthyroid state, and one patient became spontaneously hypothyroid [25] . Thus, subclinical hyperthyroidism should not necessarily be considered as a pre-thyrotoxic condition in Graves' disease.
To better define the overall severity of Graves' disease at onset, we assigned a score to the individual components of the Merseburg triad, weighing their severity, and developed a cumulative score (CSS) given by the sum of each score. Applying this evaluation system, the overall severity of Graves' disease was mild in one-fifth to one-quarter of patients at diagnosis, and less than half of the patients had severe disease. The CSS, at least in this study, was not intended to be a predictive model for the outcome of ATD treatment, as the Graves' Recurrent Events After Therapy (GREAT) score recently proposed by a Dutch group [26] . However, the severity score was associated with the risk of poorly controlled hyperthyroidism at 6 months and, to a lesser extent, at 12 months of ATD treatment.
In summary, the results of this study show that in Italy, at variance with what observed in the past, a relevant proportion of patients at diagnosis have mild to moderate Graves' disease; about half of them have no goiter, slightly less than one-fifth have subclinical hyperthyroidism, and only 20 % have GO. The mechanism responsible for these changes is unknown. It may be related to the effect of iodized salt prophylaxis in the last decades, which is associated with a drop in goiter prevalence [27] . In addition, the increase in iodine intake may favor the occurrence of Graves' disease with coexistent chronic autoimmune thyroiditis. These intermediate forms would be characterized by a milder hyperthyroidism. 4 Thyroid volume in the present study and in two previous studies from Italy [11, 23] In conclusion, comparing these results with those of two previous studies from Italy, we suggest that the clinical phenotype of Graves' disease is milder than in the past, and this may be due to both earlier diagnosis and treatment, and improved iodine nutrition.
